查看購物車
  • Simplified Chinese
  • English
  • Japanese
2031年亞太地區生物製劑市場預測 - 區域分析 - 按產品、應用、來源和製造
市場調查報告書
商品編碼
1764940

2031年亞太地區生物製劑市場預測 - 區域分析 - 按產品、應用、來源和製造

Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing
出版日期: | 出版商: The Insight Partners | 英文 163 Pages | 訂單完成後即時交付

價格

2023 年亞太生物製劑市場價值為 1,015.905 億美元，預計到 2031 年將達到 4,170.829 億美元；預計 2023 年至 2031 年的複合年成長率為 19.3%。

發展中地區生物技術發展推動亞太生物製劑市場

現代生物技術的許多應用都需要抗體，從基礎研究到創新的醫學治療方法。治療性抗體的開發為治療各種疾病開闢了新的途徑，證明了這些粒子的轉化能力。抗體在診斷中也至關重要，因為它們提供了準確可靠的疾病識別方法。各國政府的支持日益增多、公私合作夥伴關係日益加強、疾病狀況的不斷變化以及資金活動的不斷增加，正在廣泛提升亞太地區、南美洲和中美洲以及中東和非洲等地區生物技術產業的業績。阿拉伯聯合大公國、沙烏地阿拉伯、阿曼、馬斯喀特、巴林、台灣、馬來西亞、印度、中國大陸、新加坡和日本等國家和地區是生物技術產業利潤豐厚的市場。生物技術、遺傳學和細胞生物學的進步有助於發現多種潛在的標靶治療藥物。生物技術是中國的戰略產業。 「中國製造2025」計畫強調支持高科技產品（包括創新藥物）製造的研發能力。該計劃旨在引導中國製藥公司瞄準特定領域，以促進生物技術創新並提升出口。亞洲國家更注重利用基因組學、蛋白質組學和生物標記方面的進步進行診斷和治療。因此，發展中地區生物技術產業的持續發展預計將在未來幾年為生物製劑市場創造機會。

亞太生物製劑市場概覽

亞太地區的生物製劑市場分為中國、日本、印度、韓國、澳洲和亞太其他地區。該地區的市場成長得益於大量患有遺傳疾病的患者以及各國政府對醫療研發投入的增加。在過去幾年中，中國人們對生物製劑益處的認知顯著提高。此外，當地獲得細胞株表徵的各種測試服務的管道也有所增加，許多產品從臨床前開發到商業化都有所發布，這對市場的成長產生了積極的影響。近年來，科學家和衛生當局致力於強調如何有效利用生物製劑來研究和治療疾病以及開發藥物和醫療器材。他們也努力加強對先天性殘疾發展機制的認知。三星生物製劑公司已與中國生物技術公司 GeneQuantum Healthcare 簽署合作協議，共同開發用於治療非小細胞肺癌 (NSCLC)、三陰性乳癌 (TNBC) 和其他實體腫瘤的抗體藥物偶聯物 (ADC)。

亞太地區生物製劑市場收入及預測（2031年）（百萬美元）

亞太地區生物製劑市場細分

亞太生物製劑市場分為產品、應用、來源、製造和國家。

根據產品類型，亞太生物製劑市場細分為單株抗體、疫苗、重組荷爾蒙/蛋白質、細胞和基因療法以及其他。單株抗體在2023年佔據了最大的市場。

從應用角度來看，亞太生物製劑市場主要分為癌症、傳染病、自體免疫疾病等。 2023年，癌症領域佔據了最大的市場。

依來源分類，亞太生物製劑市場分為哺乳動物生物製劑和微生物生物製劑。 2023年，哺乳動物生物製劑市場佔有較大佔有率。

根據製造方式，亞太生物製劑市場分為外包和內部製造。 2023年，外包部分佔據了更大的市場。

依國家分類，亞太生物製劑市場分為中國、印度、日本、韓國、澳洲和亞太其他地區。 2023年，中國佔據了亞太生物製劑市場的主導地位。

AbbVie Inc、輝瑞公司、三星生物製品有限公司、ADMA Biologics, Inc.、無錫生物製品有限公司、Catalent Inc、AGC Biologics AS、阿斯利康公司、安進公司、Nitto Avecia 和 Quality Assistance sa 是亞太生物製劑市場的一些領先公司。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：亞太生物製劑市場－關鍵市場動態

  • 市場促進因素
    • 慢性病盛行率不斷上升
    • 傾向外包製造業務
  • 市場限制
    • 生物製劑成本高
  • 市場機會
    • 發展中地區生物技術的演變
    • 基因和細胞治療在生物製劑領域的進展
  • 未來趨勢
    • 企業的策略舉措
  • 促進因素和限制因素的影響：

第5章：生物製劑市場－亞太地區分析

  • 2021-2031年亞太地區生物製劑市場收入
  • 亞太地區生物製劑市場預測分析

第6章：亞太生物製劑市場分析 - 按產品

  • 單株抗體
  • 疫苗
  • 重組荷爾蒙/蛋白質
  • 細胞和基因治療
  • 其他

第7章：亞太生物製劑市場分析－依應用

  • 癌症
  • 傳染病
  • 自體免疫疾病
  • 其他

第8章：亞太生物製劑市場分析 - 按來源

  • 哺乳動物
  • 微生物

第9章：亞太生物製劑市場分析－依製造

  • 外包
  • 內部

第10章：亞太生物製劑市場－國家分析

  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 亞太其他地區

第 11 章：產業格局

  • 概述
  • 市場計劃
  • 夥伴關係與合作
  • 其他發展

第12章：公司簡介

  • AbbVie Inc
  • Pfizer Inc
  • Samsung Biologics Co Ltd
  • ADMA Biologics, Inc.
  • WuXi Biologics Inc
  • Catalent Inc
  • AGC Biologics AS
  • AstraZeneca Plc
  • Amgen Inc
  • Nitto Avecia
  • Quality Assistance s.a.

第 13 章：附錄

Product Code: BMIRE00031590

The Asia Pacific biologics market was valued at US$ 1,01,590.5 million in 2023 and is expected to reach US$ 4,17,082.9 million by 2031; it is estimated to register a CAGR of 19.3% from 2023 to 2031.

Evolution of Biotechnology in Developing Regions Fuels Asia Pacific Biologics Market

Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.

Asia Pacific Biologics Market Overview

The biologics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in the region is driven by a large pool of patients living with genetic conditions and increasing investments in healthcare R&D by governments of respective countries. Over the past few years, there has been a significant rise in awareness about the benefits of biologics in China. Moreover, there was a rise in local access to a broad range of testing services for cell line characterization and many release from preclinical development to commercialization, creating a positive impact on the growth of the market. In recent years, scientists and health authorities have made efforts to highlight how biologics could be effectively utilized to study and treat diseases and develop pharmaceuticals and medical devices. They are also striving to strengthen their knowledge based on the mechanism of development of congenital disabilities. Samsung Biologics has signed a partnership agreement with China Biotech GeneQuantum Healthcare for the development of antibody-drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors.

Asia Pacific Biologics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Biologics Market Segmentation

The Asia Pacific biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Asia Pacific biologics market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Asia Pacific biologics market.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Asia Pacific Biologics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Preference for Outsourcing Manufacturing Operations
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
  • 4.3 Market Opportunities
    • 4.3.1 Evolution of Biotechnology in Developing Regions
    • 4.3.2 Gene and Cell Therapy Advancements in Biologics
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Companies
  • 4.5 Impact of Drivers and Restraints:

5. Biologics Market - Asia Pacific Analysis

  • 5.1 Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
  • 5.2 Asia Pacific Biologics Market Forecast Analysis

6. Asia Pacific Biologics Market Analysis - by Product

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Overview
    • 6.1.2 Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Vaccine
    • 6.2.1 Overview
    • 6.2.2 Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Recombinant Hormones/Proteins
    • 6.3.1 Overview
    • 6.3.2 Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Cell and Gene Therapy
    • 6.4.1 Overview
    • 6.4.2 Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Biologics Market Analysis - by Application

  • 7.1 Cancer
    • 7.1.1 Overview
    • 7.1.2 Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Infectious Diseases
    • 7.2.1 Overview
    • 7.2.2 Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Autoimmune Diseases
    • 7.3.1 Overview
    • 7.3.2 Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Biologics Market Analysis - by Source

  • 8.1 Mammalian
    • 8.1.1 Overview
    • 8.1.2 Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Microbial
    • 8.2.1 Overview
    • 8.2.2 Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Biologics Market Analysis - by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 In-house
    • 9.2.1 Overview
    • 9.2.2 In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Biologics Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 China: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.2.2 China: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.2.3 China: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.2.4 China: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.3 India: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 India: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.3.2 India: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.3.3 India: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.3.4 India: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.4 Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Japan: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.4.2 Japan: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.4.3 Japan: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.4.4 Japan: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.5 South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 South Korea: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.5.2 South Korea: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.5.3 South Korea: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.5.4 South Korea: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.6 Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 Australia: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.6.2 Australia: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.6.3 Australia: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.6.4 Australia: Asia Pacific Biologics Market Share - by Manufacturing
      • 10.1.1.7 Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Product
        • 10.1.1.7.2 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Application
        • 10.1.1.7.3 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Source
        • 10.1.1.7.4 Rest of Asia Pacific: Asia Pacific Biologics Market Share - by Manufacturing

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Market Initiative
  • 11.3 Partnerships and Collaborations
  • 11.4 Other Developments

12. Company Profiles

  • 12.1 AbbVie Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Samsung Biologics Co Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ADMA Biologics, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 WuXi Biologics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Catalent Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AGC Biologics AS
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AstraZeneca Plc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Amgen Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Nitto Avecia
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Quality Assistance s.a.
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About Us

List Of Tables

  • Table 1. Asia Pacific Biologics Market Segmentation
  • Table 2. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Product
  • Table 4. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
  • Table 5. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Source
  • Table 6. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Manufacturing
  • Table 7. Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 9. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 10. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 11. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 12. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 13. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 14. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 15. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 16. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 17. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 18. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 19. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 20. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 21. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 22. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 23. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 24. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 25. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 26. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 29. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 30. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 31. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing

List Of Figures

  • Figure 1. Asia Pacific Biologics Market Segmentation - Country
  • Figure 2. Asia Pacific Biologics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Vaccine: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Asia Pacific Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Infectious Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Asia Pacific Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Microbial: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Asia Pacific Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. In-house: Asia Pacific Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Asia Pacific Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. China: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. India: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Japan: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. South Korea: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Australia: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Rest of Asia Pacific: Asia Pacific Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)